US FDA’s COVID Master Protocol Guidance To Maintain Influence Post-Pandemic

 
• By Derrick Gingery

Agency seeking comment on document intended to replace the just-issued guidance on COVID-19 treatment development as FDA stresses the value of master protocols for developing clinical knowledge.

Clinical research
Drugs evaluated in a master protocol are expected to have already been tested in humans, the FDA said in the guidance. • Source: Alamy

Guidance encouraging sponsors to use master protocols for coronavirus drug development also will influence US Food and Drug Administration policy on the clinical trial strategy going forward.

The FDA released a final guidance on 17 May as a COVID-19-focused document, which would remain in effect until the end of the public health emergency. But the agency...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D